Bisphosphonate mechanism of action-Reference-Cited by-同舟云学术

Bisphosphonate mechanism of action

Published:2003-01 Issue:1 Volume:5 Page:65-74
ISSN:1523-3774
Container-title:Current Rheumatology Reports
language:en
Short-container-title:Curr Rheumatol Rep

Author:

Reszka Alfred A.,Rodan Gideon A.

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s11926-003-0085-6.pdf

Reference83 articles.

1. Boyce RW, Wronski TJ, Ebert DC, et al.: Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone 1995, 16:209–213.

2. Meunier PJ, Boivin G: Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1997, 21:373–377.

3. Boivin GY, Chavassieux PM, Santora AC, et al.: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687–694. This clinical study demonstrates enhanced bone mineralization in biopsies of patients treated with alendronate for 2 to 3 years, provides mechanistic insight into the relationship between reduced turnover and prolonged secondary mineralization, leading to greater mean degree of mineralization, and provides a link between tissue-level mechanism on bone and anti-fracture efficacy.

4. Roschger P, Rinnerthaler S, Yates J, et al.: Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185–191. This clinical study demonstrates enhanced mineralization and reduced porosity in biopsies of patients treated with alendronate for 2 to 3 years. Study demonstrates more uniform mineralization in treated bone, with maintenance of normal crystal structures.

5. Tonino RP, Meunier PJ, Emkey R, et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109–3115.

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-steroidal Anti-inflammatory Drug (NSAID)-, Potassium Supplement-, Bisphosphonate-, and Doxycycline-Mediated Peptic Ulcer Effects: A Narrative Review;Cureus;2024-01-08

2. Osteolytic Bone Loss and Skeletal Deformities in a Mouse Model for Early-Onset Paget’s Disease of Bone with PFN1 Mutation Are Treatable by Alendronate;Pharmaceuticals;2023-10-02

3. Alendronate induces skeletal alterations in the chicken embryonic development model;Toxicology and Applied Pharmacology;2023-10

4. Position Statement: Atypical Femoral Fracture from the Korean Society for Bone and Mineral Research in 2023;Journal of Bone Metabolism;2023-08-31

5. Regulation of protein prenylation;Biomedicine & Pharmacotherapy;2023-08